The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Myeloproliferative Neoplasm Staging

Risk stratification for polycythemia vera essential thrombocythemia and myelofibrosis

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Myeloproliferative Neoplasm Staging?

Myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia, and primary myelofibrosis driven by JAK2 V617F, CALR, or MPL mutations along with rare triple negative cases. Disease stage rather than histology determines therapy and prognostic models combine clinical and laboratory features into integer scores.

Risk scores include IPSS at diagnosis using age, hemoglobin, leukocyte count, blast percentage, and constitutional symptoms; DIPSS during follow up; DIPSS plus adding cytogenetics, transfusion need, and platelet count; MIPSS70 and MIPSS70 plus integrating high molecular risk mutations such as ASXL1, EZH2, IDH1/2, and SRSF2; IPSET for essential thrombocythemia thrombosis risk.

Score categories range from low to very high and direct treatment from observation through cytoreduction, JAK inhibitors, and allogeneic transplantation. Patients with intermediate two or higher MIPSS70 scores or DIPSS plus high risk are candidates for transplant referral; lower categories receive symptom directed therapy and surveillance every three to six months.

Symptoms

Splenomegaly with abdominal fullness
Constitutional symptoms fever night sweats
Pruritus after warm bath in polycythemia
Erythromelalgia in thrombocythemia
Cytopenias progressing in myelofibrosis

Risk Factors

Older age at diagnosis
High molecular risk mutations
Unfavorable cytogenetics
Transfusion dependent anemia
Constitutional symptom presence

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • When risk score recalculation is needed
  • When transformation to acute leukemia suspected
  • When transplant evaluation is considered
  • When symptoms or cytopenias worsen
  • When new molecular testing becomes available

Treatment Methods

01
IPSS or DIPSS calculation at baseline
02
DIPSS plus update during follow up
03
MIPSS70 with mutation panel testing
04
IPSET for essential thrombocythemia
05
Treatment matched to risk category
06
Allogeneic transplantation for high risk
07
Periodic re staging every three to six months

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.